Literature DB >> 34672026

Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients.

C Cariti1, P Dapavo1, L Mastorino1, M Ortoncelli1, N Siliquini1, M Merli1, G Avallone1, S Giordano1, R Fabrizio1, S Susca1, A Verrone1, E Stroppiana1, P Quaglino1, S Ribero1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34672026     DOI： 10.1111/jdv.17766

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  3 in total

1.  Risankizumab shows high efficacy and maintenance in improvement of response until week 52.

Authors:  Luca Mastorino; Sara Susca; Matteo Megna; Niccolò Siliquini; Pietro Quaglino; Michela Ortoncelli; Gianluca Avallone; Marco Rubatto; Gabriella Fabbrocini; Paolo Dapavo; Simone Ribero
Journal:  Dermatol Ther       Date:  2022-02-28       Impact factor: 3.858

2.  Erythroderma related with the first dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine in a patient with psoriasis.

Authors:  Oyku Durmus; Neslihan Akdogan; Omer Karadag; Ozay Gokoz
Journal:  Dermatol Ther       Date:  2022-02-14       Impact factor: 3.858

3.  Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting.

Authors:  Matteo Megna; Luca Potestio; Elisa Camela; Gabriella Fabbrocini; Angelo Ruggiero
Journal:  Dermatol Ther       Date:  2022-07-11       Impact factor: 3.858
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.